These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36202073)

  • 1. Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.
    Haefliger S; Marston K; Alborelli I; Stauffer EJ; Gugger M; Jermann PM; Hoeller S; Tornillo L; Terracciano LM; Bihl M; Matter MS
    Pathobiology; 2023; 90(3):166-175. PubMed ID: 36202073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
    He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
    World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
    Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
    APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma compared with age-related colorectal carcinoma: a large cohort next generation sequence analysis.
    Escobar D; Jones R; Gao J; Sun L; Liao J; Yang GY
    Hum Pathol; 2020 Nov; 105():37-46. PubMed ID: 32916163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
    Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
    Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
    Jan YH; Tan KT; Chen SJ; Yip TTC; Lu CT; Lam AK
    Br J Cancer; 2022 Oct; 127(7):1304-1311. PubMed ID: 35842545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania.
    Brinzan CS; Aschie M; Cozaru GC; Deacu M; Dumitru E; Burlacu I; Mitroi A
    Medicine (Baltimore); 2022 Oct; 101(40):e30979. PubMed ID: 36221415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.